Cargando…
Reversing PD-1 Resistance in B16F10 Cells and Recovering Tumour Immunity Using a COX2 Inhibitor
SIMPLE SUMMARY: Some patients develop drug resistance to programmed cell death protein 1/programmed death-ligand 1(PD-1/PD-L1) therapy but the mechanism is unclear. Therefore, the study of drug resistance to PD-1 therapy is quite important. In this sense, we obtained B16F10-R tumours resistant to an...
Autores principales: | Pi, Chenyu, Jing, Ping, Li, Bingyu, Feng, Yan, Xu, Lijun, Xie, Kun, Huang, Tao, Xu, Xiaoqing, Gu, Hua, Fang, Jianmin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9455073/ https://www.ncbi.nlm.nih.gov/pubmed/36077671 http://dx.doi.org/10.3390/cancers14174134 |
Ejemplares similares
-
Targeting CD89 on tumor-associated macrophages overcomes resistance to immune checkpoint blockade
por: Xu, Lijun, et al.
Publicado: (2022) -
A Novel Anti-B7-H3 × Anti-CD3 Bispecific Antibody with Potent Antitumor Activity
por: Feng, Yan, et al.
Publicado: (2022) -
Neo-intline: integrated pipeline enables neoantigen design through the in-silico presentation of T-cell epitope
por: Li, Bingyu, et al.
Publicado: (2023) -
Simultaneous exposure to FcγR and FcαR on monocytes and macrophages enhances antitumor activity in vivo
por: Li, Bingyu, et al.
Publicado: (2017) -
In Vitro Effects of Selective COX and LOX Inhibitors and Their Combinations with Antineoplastic Drugs in the Mouse Melanoma Cell Line B16F10
por: Da-Costa-Rocha, Ines, et al.
Publicado: (2021)